Nanostructured recombinant cytokines: A highly stable alternative to short-lived prophylactics
Abstract
Cytokines have been widely used as adjuvants and therapeutic agents in treatments of human diseases. Despite their recognized potential as drugs, the medical use of cytokines has considerable drawbacks, mainly related to their low stability and short half-life. Such intrinsic limitations imply the administration of high doses, often prompting toxicity, undesirable side effects and greater production costs. Here, we describe a new category of mechanically stable nanostructured cytokines (TNFct and CCL4/MIP-10) that resist harsh physicochemical conditions in vitro (pH and temperature), while maintaining functionality. These bio-functional materials are produced in recombinant cell factories through cost-effective and fully scalable processes. Notably, we demonstrate their prophylactic potential in vivo showing they protect zebrafish from a lethal infection by Pseudomonas aeruginosa. (C) 2016 Elsevier Ltd. All rights reserved.
Más información
Título según WOS: | ID WOS:000385320100009 Not found in local WOS DB |
Título de la Revista: | BIOMATERIALS |
Volumen: | 107 |
Editorial: | ELSEVIER SCI LTD |
Fecha de publicación: | 2016 |
Página de inicio: | 102 |
Página final: | 114 |
DOI: |
10.1016/j.biomaterials.2016.08.043 |
Notas: | ISI |